Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 19,532 | 15,286 | 17,130 | 22,236 | 10,552 |
| TOTAL | $21,082 | $17,189 | $21,455 | $26,737 | $13,926 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $21,082 | $17,189 | $21,455 | $26,737 | $13,926 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,591 | 2,112 | 974 | 1,370 | 2,306 |
| Accrued Expenses | 1,045 | 1,622 | 1,831 | 1,134 | 1,575 |
| TOTAL | $3,635 | $3,734 | $2,805 | $2,504 | $3,881 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 595 | 299 | 319 | 179 | 737 |
| TOTAL | $595 | $299 | $319 | $179 | $737 |
| Total Liabilities | $4,230 | $4,033 | $3,124 | $2,683 | $4,618 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 28,355 | 26,503 | 19,486 | 19,486 | 19,486 |
| Common Shares | 3 | 2 | 2 | 2 | 1 |
| Retained earnings | -163,704 | -153,869 | -146,607 | -140,387 | -134,850 |
| TOTAL | $16,851 | $13,156 | $18,331 | $24,054 | $9,308 |
| Total Liabilities And Equity | $21,082 | $17,189 | $21,455 | $26,737 | $13,926 |